All News

In today's Pharmaceutical Executive Daily, UCB announces a definitive agreement to acquire Candid Therapeutics for up to $2.2 billion, a new commentary by Jeremy Richardson argues that MFN pricing and shifting policy expectations are making affordable direct-to-patient programs at scale an operational necessity rather than a strategic option, and a new article examines how a customer-based process can synchronize sales and marketing organizations for competitive advantage in pharma.

UCB enters agreement to acquire Candid Therapeutics in a deal worth up to $2.2 billion, adding BCMA-targeting T-cell engager cizutamig to expand its immunology pipeline.

Policy changes like Most-Favored Nation (MFN) Pricing are creating new operational requirements for pharmaceutical companies to prove every dollar delivers value.

Will Shrank, Aradigm Health’s CEO, discusses the importance of transparency in healthcare payments to build trust and reduce waste.

In today's Pharmaceutical Executive Daily, the FDA's Oncologic Drugs Advisory Committee votes a favorable benefit-risk profile for AstraZeneca's Truqap, FDA approves Axsome Therapeutics' Auvelity, and Pharmaceutical Executive speaks with Jeff Golfman on how global disruptions are cascading through the pharmaceutical supply chain.

FDA advisory panel backs Truqap combination in PTEN-deficient prostate cancer, signaling potential expansion into biomarker-defined mHSPC population with limited treatment options.

Jeff Golfman, founder and president of Send 123, in a conversation with Pharmaceutical Executive, discusses how rising geopolitical tensions around Iran and broader global disruptions are reshaping pharmaceutical and medical supply chains.

FDA approves Auvelity for Alzheimer’s-related agitation, marking the first therapy targeting NMDA and sigma-1 receptors for this high-burden neuropsychiatric symptom and expanding treatment options for millions of patients.

Aradigm CEO Will Shrank discusses the significant challenge payers face in predicting and managing the costs of cell and gene therapies due to their volatility and unpredictability.

In the final part of his interview, Jeff Golfman discusses how data-driven supply chain mapping and collaborative procurement models can gain traction as companies move beyond cost-focused sourcing to strengthen resilience.

Innomar’s VP of commercial strategy and innovation discusses the shifting global landscape and building relationships with pharma manufacturers.

Will Shrank, CEO of Aradigm Health, discusses the fragmented payment and delivery system and its impact on cell & gene therapies.

In today’s Pharmaceutical Executive Daily, Sanofi formally confirms its CEO leadership following a shareholder vote, US prescription drug spending is projected to surpass $1 trillion in 2026, and Inizio launches a next-generation hub services model aimed at simplifying patient access and support.

Inizio launches integrated hub services model to streamline patient access, reimbursement, and adherence, reflecting a broader industry shift toward data-driven, end-to-end patient support strategies.

A report from American Society of Health-System Pharmacists projects U.S. prescription drug spending to surpass $1T in 2026, driven largely by surging demand for GLP-1 weight-loss therapies.

Sanofi is appointing Belén Garijo chief as director and chief executive officer after its annual meeting, underscoring the company's leadership and governance changes.

RNA rewards companies that can integrate biology, data science, manufacturing, and clinical development into a single adaptive engine.

Jessica Lovett, VP of commercial strategy and innovation at Innomar, discusses the importance of meeting the needs of everyone at the table.

In the second part of his interview, Jeff Golfman notes how shelf-life constraints and shipping delays heighten drug shortage risk, prompting calls for diversified sourcing and larger inventory buffers.

Kaida Biopharma’s chair and acting CEO discusses how President Trump’s MFN policies and other regulatory actions are impacting pharma’s ability to invest in new treatments and adjusting international launch strategies.

In today's Pharmaceutical Executive Daily, Rocket Pharmaceuticals announces a $180 million sale of its rare pediatric disease priority review voucher, Teva Pharmaceutical enters a definitive agreement to acquire Emalex Biosciences for up to $900 million, and a feature article examines the pharmaceutical supply chain risks converging around the Strait of Hormuz.

The ongoing volatility in the Middle East and disruption risks tied to the Strait of Hormuz are exposing a broader but often underappreciated vulnerability in global pharmaceuticals.

Teva will acquire Emalex to add ecopipam, a late-stage pediatric Tourette syndrome candidate, ahead of a planned 2026 filing.

In an exclusive Q&A at Asembia’s AXS26 Summit, Syneos Health's vice president of strategic market access and patient support Kim Plesnarski touches on rapid digital innovation, evolving market structures, and shifting regulatory pressures.

Rocket Pharmaceuticals sells it's priority review voucher for $180M, securing non-dilutive funding to extend runway and advance gene therapy pipeline.

In the final part of her interview, Plesnarski notes how market access strategies evolve into core launch drivers as IRA timelines, pricing pressures, and digital adherence tools reshape how companies maximize value.

Dr. Stella Vnook explains how pharma pricing is likely to be impacted by various regulatory actions, such as MFN.

In the first part of his interview, Jeff Golfman, notes how The Strait of Hormuz disruption exposes broader global supply chain contraction, raising risks for vaccines, cancer therapies, and other critical medicines.